JP2007510622A - Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 - Google Patents

Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 Download PDF

Info

Publication number
JP2007510622A
JP2007510622A JP2006534362A JP2006534362A JP2007510622A JP 2007510622 A JP2007510622 A JP 2007510622A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2007510622 A JP2007510622 A JP 2007510622A
Authority
JP
Japan
Prior art keywords
antibody
gene
vie
vib
vic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510622A5 (enExample
Inventor
メスマー、ブラッドリー・ティ
キオラッツィ、ニコラス
アルベシアーノ、エミリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Publication of JP2007510622A publication Critical patent/JP2007510622A/ja
Publication of JP2007510622A5 publication Critical patent/JP2007510622A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
JP2006534362A 2003-10-08 2004-10-08 Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 Pending JP2007510622A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50947303P 2003-10-08 2003-10-08
PCT/US2004/033176 WO2005034733A2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2007510622A true JP2007510622A (ja) 2007-04-26
JP2007510622A5 JP2007510622A5 (enExample) 2007-11-22

Family

ID=34434984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534362A Pending JP2007510622A (ja) 2003-10-08 2004-10-08 Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物

Country Status (6)

Country Link
US (2) US8119340B2 (enExample)
EP (1) EP1678195A4 (enExample)
JP (1) JP2007510622A (enExample)
AU (1) AU2004279441B2 (enExample)
CA (1) CA2541360A1 (enExample)
WO (1) WO2005034733A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517260A (ja) * 2014-05-30 2017-06-29 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AU2004279441B2 (en) 2003-10-08 2010-07-01 The Feinstein Institute For Medical Research Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
NZ604003A (en) * 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
EP3957653A1 (en) * 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
DE102012212025A1 (de) * 2012-07-10 2014-01-16 Osram Gmbh Leuchtmodul
EP2741084B1 (en) 2012-12-07 2020-01-22 AVA Lifescience GmbH Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL)
EP2948469A4 (en) 2013-01-23 2016-11-02 Univ Leland Stanford Junior STABILIZED HEPATITIS B CORE POLYPEPTIDE
PL3508502T3 (pl) 2013-09-20 2023-07-17 Bristol-Myers Squibb Company Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CA2994412A1 (en) 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
BR112018003252A2 (pt) * 2015-08-24 2018-09-25 Medimmune Llc polipeptídeos mrka, anticorpos, e usos dos mesmos
WO2017044859A1 (en) 2015-09-10 2017-03-16 Affigen, Inc. Sequencing-directed selection of tumor theranostics
WO2018152452A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
CN118356488A (zh) 2017-05-30 2024-07-19 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
EP3934418A4 (en) 2019-03-08 2023-01-18 Memorial Sloan Kettering Cancer Center ADAM17 BINDING MOLECULES AND THEIR USES
EP4013794A4 (en) * 2019-08-12 2023-11-22 City of Hope Il1rap antibodies
CN113461818B (zh) * 2021-06-30 2022-01-21 徐州医科大学 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法
IL315487A (en) * 2022-03-07 2024-11-01 Agenus Inc ANTI-ILT2 antibodies and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
AU2004279441B2 (en) 2003-10-08 2010-07-01 The Feinstein Institute For Medical Research Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010057332, Ｂｌｏｏｄ， （１９９８）， ９２， ［１０， Ｓｕｐｐｌ．１ Ｐｔ．１−２］， ｐ．４３１ａ（Ａｂｓｔｒａｃｔ＃１７８４） *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517260A (ja) * 2014-05-30 2017-06-29 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用

Also Published As

Publication number Publication date
AU2004279441A1 (en) 2005-04-21
US9745364B2 (en) 2017-08-29
US20120141462A1 (en) 2012-06-07
WO2005034733A2 (en) 2005-04-21
US8119340B2 (en) 2012-02-21
US20090117095A1 (en) 2009-05-07
EP1678195A4 (en) 2008-04-23
EP1678195A2 (en) 2006-07-12
CA2541360A1 (en) 2005-04-21
AU2004279441B2 (en) 2010-07-01
WO2005034733A3 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
JP2007510622A (ja) Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物
Messmer et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
Ghiotto et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia
JP7534303B2 (ja) 新規のｌｉｌｒｂ４抗体およびその使用
Craig et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins
CN101668853B (zh) 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
JP2018102299A (ja) 膀胱癌の処置および診断のための方法および組成物
WO2003026493A2 (en) Diagnosis and treatment of diseases caused by mutations in cd72
JP2007518399A (ja) 肺癌を診断および治療する組成物並びに方法
Wang et al. B-cell receptor repertoire: recent advances in autoimmune diseases
JP2008527998A (ja) Ｎｓｃｌｃの診断のためのｇｉｔｒ抗体
US8722350B2 (en) Methods and compositions for categorizing patients
US7118912B2 (en) Methods and compositions for categorizing patients
US20250304721A1 (en) Methods for generating high affinity antibodies against fentanyl
Karp et al. Antigen stimulation in the development of chronic lymphocytic leukemia
Pandey et al. Genetics of human immunoglobulins
EP4514952A1 (en) Terminal deoxynucleotidyl transferase antibodies and uses thereof
Bhamidipati B Cell Dysregulation in Immune Mediated Diseases
CN121006619A (zh) 构建纳米抗体编码dna文库的方法及应用
Eurelings et al. Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy
Pandey et al. TWO GENES–ONE POLYPEPTIDE CHAIN Rationale In 1958 Beadle and Tatum received the Nobel prize for work demonstrating the 1 gene-1 polypeptide hypothesis in Neurospora. By contrast, in 1965 Dreyer and Bennett concluded that the Ig polypeptide chain was encoded by two genes (2
WO2006078780A2 (en) Rdc1 antibodies for the diagnosis of nsclc
MX2007008691A (en) Gitr antibodies for the diagnosis of nsclc
Neubauer et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated
Pruzanski et al. Variable region gene analysis of pathologic human autoantibodies to

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918